Open access
Open access
Powered by Google Translator Translator

Critical Care

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

12 May, 2021 | 08:45h | UTC

Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine – medRxiv

 


Perspective | Top five priorities for a new ICU director during the first year.

12 May, 2021 | 08:33h | UTC

Top Five Priorities for a New ICU Director During the First Year – ICU Management & Practice

 


Perspective | 12 things to do to improve wellbeing in the ICU.

12 May, 2021 | 08:30h | UTC

12 Things to Do to Improve Wellbeing in the ICU – ICU Management & Practice

 


Perspective | The essentials for a humanized ICU.

12 May, 2021 | 08:28h | UTC

The Essentials for a Humanised Intensive Care Unit (H-ICU) – ICU Management & Practice

 


Review: The incidence, risk, presentation, pathophysiology, treatment, and effects of perioperative acute kidney injury.

12 May, 2021 | 08:27h | UTC

The incidence, risk, presentation, pathophysiology, treatment, and effects of perioperative acute kidney injury – Canadian Journal of Anesthesiology

 


Review: Neurologic assessment of the neurocritical care patient.

12 May, 2021 | 08:24h | UTC

Neurologic Assessment of the Neurocritical Care Patient – Frontiers in Neurology

 


Mucormycosis: The ‘black fungus’ maiming Covid patients in India

11 May, 2021 | 09:14h | UTC

Mucormycosis: The ‘black fungus’ maiming Covid patients in India – BBC

See also: Potentially fatal ‘black fungus’ infections on the rise in India’s COVID-19 patients – LiveScience AND A potentially fatal fungal infection is cropping up among India’s Covid patients. – The New York Times AND WHO says virus strain in India a ‘variant of concern’ as Europe eases curbs – MedicalXpress

 

Commentary on Twitter (thread – click for more)

 


Observational study suggests an early head‐to‐pelvis computed tomography can expedite the diagnosis of potential causes in patients with out‐of‐hospital circulatory arrest without obvious etiology

11 May, 2021 | 09:10h | UTC

Early head‐to‐pelvis computed tomography in out‐of‐hospital circulatory arrest without obvious etiology – Academic Emergency Medicine (link to abstract – $ for full-text)

Commentary: Early Head-to-Pelvis CT for OHCA – Journal Feed

 


New WHO Online Course: Initial approach to the acutely ill patient with COVID-19.

10 May, 2021 | 01:21h | UTC

Clinical management of patients with COVID-19: Initial approach to the acutely ill patient – World Health Organization

 


A restrictive fluid management strategy shows promise for acute kidney injury in a pilot randomized controlled trial.

10 May, 2021 | 00:57h | UTC

Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial – Intensive Care Medicine

 

Commentary on Twitter

 


Guideline: Diagnosis and treatment of neurogenic dysphagia.

6 May, 2021 | 08:51h | UTC

Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology – Neurological Research and Practice

 


ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients

5 May, 2021 | 08:28h | UTC

Nucleic Acid–based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline

News Release: New clinical practice guideline on community acquired pneumonia – American Thoracic Society

 


Opinion | Manual in‐line stabilization during tracheal intubation: effective protection or harmful dogma?

5 May, 2021 | 08:18h | UTC

Manual in‐line stabilisation during tracheal intubation: effective protection or harmful dogma? – Anaesthesia

 


M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

4 May, 2021 | 08:52h | UTC

Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis – Critical Care Medicine (link to abstract – $ for full-text)

 


[Preprint] Preventing disproportionate mortality in ICU overload situations: Empirical evidence from the first COVID-19 wave in Europe – “transferring patients proactively out of developing hotspots to less affected regions, well before high ICU workload situations emerge, will improve patient outcomes”

4 May, 2021 | 08:42h | UTC

Preventing disproportionate mortality in ICU overload situations: Empirical evidence from the first COVID-19 wave in Europe – medRxiv

 


ISCHEMIA trial – days alive out of hospital endpoint was higher in the conservative management group vs. invasive management group at 1 month (30.8 vs 28.4 days), 1 year (362.2 vs 355.9 days), and 2 years (718.4 vs 712.1 days)

4 May, 2021 | 08:41h | UTC

Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial – JAMA Cardiology (free for a limited period)

Original study: ISCHEMIA Trial: Health-Status Outcomes with Initial Invasive vs. Conservative Care in Stable Coronary Disease AND ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease AND ISCHEMIA Trial: Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease AND ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease

 


Study: Most patients who develop a non-IgE-mediated hypersensitivity reaction to nafcillin can be safely treated with cefazolin

4 May, 2021 | 08:36h | UTC

Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections – Clinical Infectious Diseases

Related: Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin – Antimicrobial Agents & Chemotherapy

 

Commentary on Twitter

 


RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

3 May, 2021 | 05:47h | UTC

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited commentary: Tocilizumab in COVID-19: some clarity amid controversy – The Lancet

 


M-A: Tocilizumab reduces the need for mechanical ventilation in COVID-19 patients, but the randomized trials included in the analysis showed it has no significant effect on the risk of mortality or adverse events

3 May, 2021 | 05:44h | UTC

Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic Review and meta-analysis: first update – Clinical Microbiology and Infection

 


Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

3 May, 2021 | 05:43h | UTC

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 – JAMA

Editorial: Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine – JAMA

See also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention

Related: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

 


ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding – RBC transfusion at a threshold of 7 g/dL; Erythromycin infusion is suggested before endoscopy; and endoscopy is suggested within 24 hours after presentation.

3 May, 2021 | 05:27h | UTC

ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding – The American Journal of Gastroenterology

 


ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury – antimicrobials, herbal and dietary supplements, and anticancer therapeutics are the most common classes of agents

3 May, 2021 | 05:22h | UTC

ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury – The American Journal of Gastroenterology

 


Study: Patients with heart failure have a much higher incidence of pneumonia than matched individuals in the population. The development of pneumonia in these patients is associated with a 3- to 4-fold higher risk of cardiovascular and all-cause death.

3 May, 2021 | 05:18h | UTC

Incidence and Outcomes of Pneumonia in Patients With Heart Failure – Journal of the American College of Cardiology

Commentaries: Pneumonia in HF Patients Is Common, Lethal, and Preventable – TCTMD AND Outcomes of Pneumonia in Patients With Heart Failure – American College of Cardiology

 


AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

30 Apr, 2021 | 08:25h | UTC

Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – Stroke

News release: Guidance on treatment for rare blood clots and low platelets related to COVID-19 vaccine – American Heart Association

Related: ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 


Study with 6.9 million people in England shows severe Covid-19 in young people can mostly be explained by obesity – At a BMI of more than 23 kg/m2, there was a linear increase in risk of severe COVID-19

30 Apr, 2021 | 08:22h | UTC

Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study – The Lancet Diabetes & Endocrinology

Commentaries: Severe COVID in young people can mostly be explained by obesity – new study – The Conversation AND Obesity studies highlight severe COVID outcomes, even in young adults – CIDRAP AND Expert reaction to study looking at a potential link between body weight and risk of severe COVID-19, especially for younger adults – Science Media Centre

 

Commentary on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

No spam, just news.